Guardant Health to Share Data Supporting Critical Role of Blood-Based Testing in Colorectal Cancer Screening at ACG 2024
Guardant Health (GH) announced upcoming presentations at the American College of Gastroenterology (ACG) 2024 Annual Meeting highlighting the importance of blood-based colorectal cancer (CRC) screening. A key study of over 350,000 patients revealed that less than 50% of patients completed recommended repeat stool-based CRC screening over a four-year period. The company will also present data from the ECLIPSE study examining one-year outcomes of individuals tested with their Shield™ blood test, showing no difference in non-colorectal malignancy rates between positive and negative test results.
Guardant Health (GH) ha annunciato le prossime presentazioni al Congresso Annuale del Collegio Americano di Gastroenterologia (ACG) 2024, evidenziando l'importanza dello screening per il cancro colorettale (CRC) basato su sangue. Uno studio chiave su oltre 350.000 pazienti ha rivelato che meno del 50% dei pazienti ha completato lo screening CRC raccomandato basato su feci nel corso di un periodo di quattro anni. L'azienda presenterà anche dati dallo studio ECLIPSE che esamina i risultati a un anno di individui testati con il loro test sanguigno Shield™, mostrando nessuna differenza nei tassi di malignità non colorettale tra risultati di test positivi e negativi.
Guardant Health (GH) anunció próximas presentaciones en el Congreso Anual del Colegio Americano de Gastroenterología (ACG) 2024, destacando la importancia de la detección del cáncer colorrectal (CRC) basado en sangre. Un estudio clave con más de 350,000 pacientes reveló que menos del 50% de los pacientes completaron el screening repetido de CRC basado en heces durante un período de cuatro años. La empresa también presentará datos del estudio ECLIPSE que examina los resultados a un año de personas sometidas a su prueba de sangre Shield™, mostrando ninguna diferencia en las tasas de malignidad no colorrectal entre los resultados de test positivos y negativos.
Guardant Health (GH)는 2024년 미국 위장병학회(ACG) 연례 회의에서 혈액 기반 대장암(CRC) 검진의 중요성을 강조하는 발표를 예정하고 있다고 발표했습니다. 35만 명 이상의 환자를 대상으로 한 주요 연구에 따르면, 50% 미만의 환자만이 4년 동안 권장되는 반복 대변 기반 CRC 검진을 완료했습니다. 또한 이 회사는 Shield™ 혈액 검사로 검사를 받은 개인의 1년 결과를 조사하는 ECLIPSE 연구의 데이터를 발표하며, 양성과 음성 검사 결과 간의 비대장 악성종양 발생률에 차이가 없음을 보여주었습니다.
Guardant Health (GH) a annoncé de futures présentations lors du Congrès Annuel du Collège Américain de Gastroentérologie (ACG) 2024, soulignant l'importance du dépistage du cancer colorectal (CRC) basé sur le sang. Une étude clé portant sur plus de 350 000 patients a révélé que moins de 50 % des patients ont complété le dépistage répétitif du CRC basé sur les selles sur une période de quatre ans. L'entreprise présentera également des données de l'étude ECLIPSE examinant les résultats d'un an des individus testés avec leur test sanguin Shield™, montrant aucune différence dans les taux de malignité non colorectale entre les résultats de test positifs et négatifs.
Guardant Health (GH) kündigte kommende Präsentationen beim Jahrestreffen des American College of Gastroenterology (ACG) 2024 an, die die Bedeutung von blutbasiertem Screening auf kolorektalen Krebs (CRC) hervorheben. Eine Schlüsselstudie mit über 350.000 Patienten ergab, dass weniger als 50 % der Patienten die empfohlene wiederholte Stuhluntersuchung auf CRC über einen Zeitraum von vier Jahren abgeschlossen haben. Das Unternehmen wird auch Daten aus der ECLIPSE-Studie präsentieren, die die Ergebnisse nach einem Jahr von Personen untersucht, die mit ihrem Shield™-Bluttest getestet wurden und keine Unterschiede in den Raten nicht-kolorektaler Malignitäten zwischen positiven und negativen Testergebnissen zeigte.
- Study of 350,000+ patients validates market opportunity for blood-based testing alternatives
- Shield blood test shows promising safety profile with no increased false cancer detection rate
- Presidential Poster Award recognition at ACG 2024 for real-world adherence study
- Current data suggests poor patient compliance with existing screening methods, indicating potential market adoption challenges
Insights
The real-world data from 350,000 patients showing
The ECLIPSE study findings regarding false positives are particularly noteworthy - showing no increased risk of non-colorectal malignancies in Shield-positive results compared to negatives. This helps validate the test's specificity and could reduce concerns about unnecessary follow-up procedures.
While this research strengthens Shield's market position in the
Less than half of patients who underwent stool-based CRC screening completed recommended repeat testing
Guardant and its research partners will share real-world data demonstrating poor patient compliance with repeat stool-based screening. A study of more than 350,000 patients shows that less than half of patients who underwent stool-based CRC screening completed the retesting recommended in clinical guidelines over the following four-year period, highlighting the need for alternative options to improve overall compliance to repeat testing.
A second presentation will report on the one-year outcomes of individuals tested with Guardant’s Shield™ blood test for CRC screening in the ECLIPSE study to understand the implications of “false positive” results. Study results demonstrate that the rate of non-colorectal malignancies does not differ in those who tested positive with Shield compared to those who tested negative.
“Research has clearly demonstrated the value of colorectal cancer screening in detecting cancer early, when it is most treatable, but screening is only effective if an individual completes the test,” said Craig Eagle, MD, chief medical officer at Guardant Health. “We look forward to sharing findings at the ACG meeting that support the potential of a blood-based screening option like the Shield test to improve overall screening rates among the millions of eligible individuals who may prefer a more pleasant screening option.”
Guardant Health and collaborator presentations at ACG 2024
Presentation |
Title |
Time / Location |
Tuesday, October 29 |
||
Evaluating the Risk of Non-Colorectal Cancers in Individuals With a False Positive Blood-Based Colorectal Cancer Screening Test |
8:30am ET / Terrace Ballroom 2-3 |
|
Real-World Adherence to Repeat Testing for Stool-Based Non-Invasive Colorectal Cancer Screening Tests Among Individuals With Average Risk – ACG Presidential Poster Award winner |
10:30am-4:00pm ET / Exhibit Hall E |
|
The full abstracts for Guardant Health and a list of all abstracts being presented at the ACG Annual Meeting can be found on the ACG meeting website.
For information and updates from the conference, follow Guardant Health on LinkedIn, X (Twitter) and Facebook.
About Guardant Health
Guardant Health is a leading precision oncology company focused on guarding wellness and giving every person more time free from cancer. Founded in 2012, Guardant is transforming patient care and accelerating new cancer therapies by providing critical insights into what drives disease through its advanced blood and tissue tests, real-world data and AI analytics. Guardant tests help improve outcomes across all stages of care, including screening to find cancer early, monitoring for recurrence in early-stage cancer, and treatment selection for patients with advanced cancer. For more information, visit guardanthealth.com and follow the company on LinkedIn, X (Twitter) and Facebook.
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of federal securities laws, including statements regarding the potential utilities, values, benefits and advantages of Guardant Health’s liquid biopsy tests or assays, which involve risks and uncertainties that could cause the actual results to differ materially from the anticipated results and expectations expressed in these forward-looking statements. These statements are based on current expectations, forecasts and assumptions, and actual outcomes and results could differ materially from these statements due to a number of factors. These and additional risks and uncertainties that could affect Guardant Health’s financial and operating results and cause actual results to differ materially from those indicated by the forward-looking statements made in this press release include those discussed under the captions “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operation” and elsewhere in its Annual Report on Form 10-K for the year ended December 31, 2023, and in its other reports filed with or furnished to the Securities and Exchange Commission thereafter. The forward-looking statements in this press release are based on information available to Guardant Health as of the date hereof, and Guardant Health disclaims any obligation to update any forward-looking statements provided to reflect any change in its expectations or any change in events, conditions, or circumstances on which any such statement is based, except as required by law. These forward-looking statements should not be relied upon as representing Guardant Health’s views as of any date subsequent to the date of this press release.
View source version on businesswire.com: https://www.businesswire.com/news/home/20241028597268/en/
Investor Contact:
Zarak Khurshid
investors@guardanthealth.com
Media Contact:
Michael Weist
press@guardanthealth.com
+1 317-371-0035
Source: Guardant Health, Inc.
FAQ
What did Guardant Health's (GH) study reveal about stool-based CRC screening compliance?
What are the key findings about Guardant Health's (GH) Shield blood test from the ECLIPSE study?
When will Guardant Health (GH) present their colorectal cancer screening data at ACG 2024?
